Conmed (CNMD) Misses Q4 EPS by 1c; Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CONMED (CNMD) PT Raised to $56 at Summer Street Post Q4
January 28, 2015 8:18 AM ESTSummer Street analyst Mark Landy reiterated a Buy rating and boosted his price target on CONMED (NASDAQ: CNMD) to $56.00 (from $46.00)
Landy commented, "Yesterday CNMD reported 4Q14 revenues in line with the January 14 preannouncement. Revenues and EPS were $195MM and $0.53, respectively. As CNMD carries meaningful FX hedges, given its outsized exposure to international markets (~50%... More
